The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

TNXP READ THE FULL TNXP RESEARCH REPORT Financial Update On July 25, 2025, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ...

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK, July 29, 2025 /PRNewswire/ ...

LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong ...

If drug developers are allowed to skip this step, it will mean that, in the near future, the first living body a new drug is ...

Procedural flexibility incorporated into many cancer clinical trials during the COVID-19 pandemic had no long-term negative ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

Decentralized Clinical Trials (DCTs) are transforming how we collect clinical data, but this evolution brings unprecedented challenges in data quality, complexity, and integration.

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...